Kenneth Miller, President and CEO of BioVentrix said, "We are pleased to have Steve Healy as the new Chairman of the Board. He is well suited to oversee BioVentrix in our next phase of growth given his deep experience in the cardiovascular medical device market segment, highlighted by his leadership in the Cardiac Surgery Division of St. Jude Medical, Inc., which included the development and commercialization of heart valves."
"BioVentrix is well positioned to improve outcomes in the ischemic heart failure market," commented Mr. Healy. "I am honored to accept the role of Chairman and I look forward to working with Ken and the BioVentrix team as we continue to drive adoption of our products and expand our current technologies."
Mr. Healy has over thirty years of experience in the medical device industry and most recently served as General Manager of Global Spine for Zimmer Biomet, a worldwide leader in joint replacement solutions. Prior to joining Zimmer Biomet, he served as Chairman of the Board and Chief Executive Officer of Lumen Biomedical Inc., an interventional cardiology company. Before joining Lumen Biomedical, he was Chief Executive Officer of Disc Dynamics, Inc., an orthopedic medical technology company where he served from July 2002 to June 2009. Prior to Disc Dynamics, he was President of the Cardiac Surgery Division at St. Jude Medical, where he held a variety of senior management positions before being promoted to President. Mr. Healy joined St. Jude Medical in 1983.
BioVentrix, a privately held medical technology company headquartered in San Ramon, Calif., is focused on developing and commercializing minimally invasive therapies for treating HF. The company recently received CE mark certification for its closed-chest Revivent-TC™ TransCatheter Ventricular Enhancement System for plication of scar tissue in post-MI, ischemic cardiomyopathy patients. Placement of the Revivent-TC System via the LIVE™ procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a catheter-based approach. The anchors are then pulled toward one another, effectively excluding the scarred and non-functioning heart wall. Ventricular volume is immediately reduced as a result of the exclusion, by as much as 30-40 percent1.
Click here for corporate video with animation
Note: The Revivent-TC System is approved for sale in Europe; it is not approved for sale in the United States.
1Wechsler, A. et al., Clinical benefits twelve months after less invasive ventricular restoration operations without ventriculotomy. Annual meeting of the European Society of Cardio-Thoracic Surgery, 07 Oct. 2013, Vienna, Austria.
Logo - http://photos.prnewswire.com/prnh/20151207/293907LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/steven-healy-appointed-as-chairman-of-the-board-of-directors-of-bioventrix-inc-300338378.html
SOURCE BioVentrix, Inc.